BRAF and melanoma: Regarding patients with advanced melanoma, nivolumab was the most cost-effective treatment option in BRAF wild-type and BRAF mutant patients, as demonstrated by the Markov model developed to estimate the lifetime costs and benefits of nivolumab versus ipilimumab and dacarbazine (for BRAF wild-type) and versus ipilimumab, dabrafenib, and vemurafenib (for BRAF mutant patients) [62].